Brought to you by 
KemPharm nets $23.5mm in FOPO
11 Oct 2018
Executive Summary
KemPharm Inc. (pipeline of prodrugs for multiple CNS indications) netted $23.5mm through the public sale of 8.3mm shares at $3. The company plans to use the proceeds to fund its lead extended-release dexmethylphenidate prodrug candidates for attention deficit hyperactivity disorder (ADHD); an NDA submission for KP415 (anticipated Q1 2019); and the initiation of a pivotal trial for preclinical KP484 (expected to begin next year). Earlier this year, KemPharm's first prodrug--abuse-deterrent Apadaz (benzhydrocodone/acetaminophen) for short-term management of acute pain--was approved by the FDA.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
KemPharm nets $23.5mm in FOPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice